Sanofi SA's Fiscal Year is From January To December - All Figures are in EUR, Billions.
The item "Operating-Income" stands at 8.57 Billion Euros for the trailing twelve months (TTM) period ending 09/30/2025.
Sanofi SA's third quarter result of 3.62 Billion EUR for the item "Operating Income" represents an increase of 145.79 percent compared to it's second quarter result.
Also, Sanofi SA's third quarter result of 3.62 Billion EUR for the item "Operating Income" represents a decrease of -0.33 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Sanofi SA's third quarter result of 8.57 Billion EUR for the item "Operating Income" represents a decrease of -0.14 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 7.83 percent compared to the value the year prior.
The 1 year change in percent is 7.83.
The 3 year change in percent is 6.77.
The 5 year change in percent is -31.54.
The 10 year change in percent is 26.00.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Operating Income | 905,699,262,464.00 |
![]() | Johnson & Johnson - Operating Income | 486,508,953,600.00 |
![]() | AbbVie Inc - Operating Income | 399,570,305,024.00 |
![]() | Roche Holding AG - Operating Income | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Operating Income | 280,205,508,085.11 |